RACCOR: Effect of Implementation of Enhanced Recovery After Surgery on 3-year Survival After Colorectal Surgery for Cancer

• Sponsor: University Hospital, Grenoble (Other)
• Overall Status: Completed
• CT.gov ID: NCT05002855
• Collaborator: (none)
• Enrollment: 1,001
• Location: 1
• Actual Duration (Months): 5.3
• Patients Per Site Per Month: 189.2

Study Details

Study Description

Brief Summary

Several recent studies have shown that the Enhanced Recovery After Surgery (ERAS) protocol reduces morbidity and mortality and shortens the length of stay compared to conventional recovery strategy (pre-ERAS). The aim of this study was to evaluate the effect of the implementation of this protocol on 3-year overall survival and postoperative outcome in patients undergoing colorectal resection for cancer.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer	Other: Enhanced Recovery After Surgery (ERAS)

Study Design

• Study Type: Observational
• Actual Enrollment: 1001 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Effect of Implementation of Enhanced Recovery After Surgery (ERAS) Protocol on 3-year Survival After Colorectal Surgery for Cancer - a Retrospective Cohort of 1001 Patients
• Actual Study Start Date: Jan 20, 2021
• Actual Primary Completion Date: May 30, 2021
• Actual Study Completion Date: Jun 30, 2021

Arms and Interventions

Arm	Intervention/Treatment
Enhanced Recovery After Surgery (ERAS)	Other: Enhanced Recovery After Surgery (ERAS); Multidisciplinary approach to perioperative care.
Conventional Recovery Strategy (pre-ERAS)

Outcome Measures

Primary Outcome Measures

1. Evaluate the effect of the implementation of this protocol on 3-year overall survival. [3 years]

   3-year overall survival rate

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• Aadult patients, who had undergone resection for colorectal cancer or a precancerous lesion and were cared for using the ERAS protocol or received conventional care (pre-ERAS).

• Informed patients

Exclusion Criteria:

• Patients presenting or developing peritoneal cancer,

• Patients having resection for palliative reasons,

• Patients those under curatorship or tutelage

• Opposed patients

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Jean-Luc Faucheron	Grenoble		France

Sponsors and Collaborators

• University Hospital, Grenoble

Investigators

• Study Director: Jean-Luc Faucheron, CHU Grenoble Alpes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University Hospital, Grenoble
• ClinicalTrials.gov Identifier: NCT05002855
• Other Study ID Numbers: 2021
• First Posted: Aug 12, 2021
• Last Update Posted: Sep 14, 2021
• Last Verified: Sep 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Colorectal Neoplasms

Study Results

No Results Posted as of Sep 14, 2021